A 160 CDI (82 Hp) Autotronic 3-Dr

Тема в разделе "A-klasse (169)", создана пользователем forxalex, 29 июн 2010.

  1. forxalex

    forxalex Well-Known Member

    Регистрация:
    15 июн 2010
    Сообщения:
    633
    Симпатии:
    0
    <table width="100%" align="center" bgcolor="#006c8a" cellspacing="1"><tbody><tr bgcolor="#ffffff"><td colspan="2" style="color: rgb(255, 255, 255); font-size: 14px;" align="center" bgcolor="#006c8a"> КУЗОВ</td></tr><tr style="font-size: 12px;" bgcolor="#f7f3f7"><td> Тип кузова</td><td> Универсал </td></tr><tr style="font-size: 12px;" bgcolor="#e0e0e0"><td> Количество дверей</td><td> 3/5 </td></tr><tr style="font-size: 12px;" bgcolor="#f7f3f7"><td> Количество мест</td><td> 5 </td></tr><tr style="font-size: 12px;" bgcolor="#e0e0e0"><td> Длина</td><td> 3838 мм</td></tr><tr style="font-size: 12px;" bgcolor="#f7f3f7"><td> Ширина</td><td> 1764 мм</td></tr><tr style="font-size: 12px;" bgcolor="#e0e0e0"><td> Высота</td><td> 1595 мм</td></tr><tr style="font-size: 12px;" bgcolor="#f7f3f7"><td> Колесная база</td><td> 2568 мм</td></tr><tr style="font-size: 12px;" bgcolor="#e0e0e0"><td> Колея передняя</td><td> 1552 мм</td></tr><tr style="font-size: 12px;" bgcolor="#f7f3f7"><td> Колея задняя</td><td> 1547 мм</td></tr><tr style="font-size: 12px;" bgcolor="#e0e0e0"><td> Объем багажника максимальный</td><td> 1995 л</td></tr><tr style="font-size: 12px;" bgcolor="#f7f3f7"><td> Объем багажника минимальный</td><td> 435 л</td></tr><tr bgcolor="#ffffff"><td colspan="2" style="color: rgb(255, 255, 255); font-size: 14px;" align="center" bgcolor="#006c8a"> ДВИГАТЕЛЬ</td></tr><tr style="font-size: 12px;" bgcolor="#e0e0e0"><td> Расположение двигателя</td><td> Спереди, поперечно </td></tr><tr style="font-size: 12px;" bgcolor="#f7f3f7"><td> Объем двигателя</td><td> 1991 см<sup>3</sup></td></tr><tr style="font-size: 12px;" bgcolor="#e0e0e0"><td> Мощность</td><td> 82 л.с.</td></tr><tr style="font-size: 12px;" bgcolor="#f7f3f7"><td> При оборотах</td><td> 4200 </td></tr><tr style="font-size: 12px;" bgcolor="#e0e0e0"><td> Крутящий момент</td><td> 180/1400 н*м</td></tr><tr style="font-size: 12px;" bgcolor="#f7f3f7"><td> Система питания</td><td> Дизель Common rail </td></tr><tr style="font-size: 12px;" bgcolor="#e0e0e0"><td> Наличие турбонаддува</td><td> Турбонаддув </td></tr><tr style="font-size: 12px;" bgcolor="#f7f3f7"><td> Газораспределительный механизм</td><td> - </td></tr><tr style="font-size: 12px;" bgcolor="#e0e0e0"><td> Расположение цилиндров</td><td> Рядный </td></tr><tr style="font-size: 12px;" bgcolor="#f7f3f7"><td> Количество цилиндров</td><td> 4 </td></tr><tr style="font-size: 12px;" bgcolor="#e0e0e0"><td> Диаметр цилиндра</td><td> 83 мм</td></tr><tr style="font-size: 12px;" bgcolor="#f7f3f7"><td> Ход поршня</td><td> 92 мм</td></tr><tr style="font-size: 12px;" bgcolor="#e0e0e0"><td> Степень сжатия</td><td> 18 </td></tr><tr style="font-size: 12px;" bgcolor="#f7f3f7"><td> Количество клапанов на цилиндр</td><td> 4 </td></tr><tr style="font-size: 12px;" bgcolor="#e0e0e0"><td> Топливо</td><td> дизельное топливо </td></tr><tr bgcolor="#ffffff"><td colspan="2" style="color: rgb(255, 255, 255); font-size: 14px;" align="center" bgcolor="#006c8a"> ТРАНСМИССИЯ</td></tr><tr style="font-size: 12px;" bgcolor="#f7f3f7"><td> Привод</td><td> Передний </td></tr><tr style="font-size: 12px;" bgcolor="#e0e0e0"><td> Кол-во передач (автомат коробка)</td><td> Вариатор </td></tr><tr style="font-size: 12px;" bgcolor="#f7f3f7"><td> Передаточное отношение главной пары</td><td> 3.31 </td></tr><tr bgcolor="#ffffff"><td colspan="2" style="color: rgb(255, 255, 255); font-size: 14px;" align="center" bgcolor="#006c8a"> ПОДВЕСКА</td></tr><tr style="font-size: 12px;" bgcolor="#e0e0e0"><td> Тип задней подвески</td><td> Винтовая пружина </td></tr><tr style="font-size: 12px;" bgcolor="#f7f3f7"><td> Тип передней подвески</td><td> Амортизационная стойка </td></tr><tr bgcolor="#ffffff"><td colspan="2" style="color: rgb(255, 255, 255); font-size: 14px;" align="center" bgcolor="#006c8a"> ТОРМОЗНАЯ СИСТЕМА</td></tr><tr style="font-size: 12px;" bgcolor="#e0e0e0"><td> Передние тормоза</td><td> Дисковые </td></tr><tr style="font-size: 12px;" bgcolor="#f7f3f7"><td> Задние тормоза</td><td> Дисковые </td></tr><tr style="font-size: 12px;" bgcolor="#e0e0e0"><td> АБС</td><td> есть </td></tr><tr bgcolor="#ffffff"><td colspan="2" style="color: rgb(255, 255, 255); font-size: 14px;" align="center" bgcolor="#006c8a"> РУЛЕВОЕ УПРАВЛЕНИЕ</td></tr><tr style="font-size: 12px;" bgcolor="#f7f3f7"><td> Тип рулевого управления</td><td> Шестерня-рейка </td></tr><tr style="font-size: 12px;" bgcolor="#e0e0e0"><td> Усилитель руля</td><td> + </td></tr><tr bgcolor="#ffffff"><td colspan="2" style="color: rgb(255, 255, 255); font-size: 14px;" align="center" bgcolor="#006c8a"> ЭКСПЛУАТАЦИОННЫЕ ПОКАЗАТЕЛИ</td></tr><tr style="font-size: 12px;" bgcolor="#f7f3f7"><td> Максимальная скорость</td><td> 165 км/ч</td></tr><tr style="font-size: 12px;" bgcolor="#e0e0e0"><td> Время разгона (0-100 км/ч)</td><td> 15.3 c</td></tr><tr style="font-size: 12px;" bgcolor="#f7f3f7"><td> Расход топлива в городе</td><td> 6.7 л/100км</td></tr><tr style="font-size: 12px;" bgcolor="#e0e0e0"><td> Расход топлива на шоссе</td><td> 4.6 л/100км</td></tr><tr style="font-size: 12px;" bgcolor="#f7f3f7"><td> Расход топлива Смешанный цикл</td><td> 4.9 л/100км</td></tr><tr style="font-size: 12px;" bgcolor="#e0e0e0"><td> Объем топливного бака</td><td> 54 л</td></tr><tr style="font-size: 12px;" bgcolor="#f7f3f7"><td> Снаряженная масса автомобиля</td><td> 1325 кг</td></tr><tr style="font-size: 12px;" bgcolor="#e0e0e0"><td> Допустимая полная масса</td><td> 1764 кг</td></tr><tr style="font-size: 12px;" bgcolor="#f7f3f7"><td> Размер шин</td><td> 185/65 R15 </td></tr><tr style="font-size: 12px;" bgcolor="#e0e0e0"><td> Размер дисков</td><td> 6J x 15 </td></tr></tbody></table>
     
  2. BrianNix

    BrianNix Well-Known Member

    Регистрация:
    25 май 2020
    Сообщения:
    12,761
    Симпатии:
    0
  3. Manuelnus

    Manuelnus New Member

    Регистрация:
    1 окт 2020
    Сообщения:
    2
    Симпатии:
    0
    A usher in II ponder led via researchers from The University of Texas MD Anderson Cancer Center start that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% open-minded comeback saying in patients with advanced pernicious peritoneal mesothelioma, a rare cancer in the lining of the abdomen. Responses occurred in patients regardless of PD-L1 enunciation account and tumor mutant burden.

    Side results indicated that the bludgeon allied with was repository and incontestable in patients with malady advancement or xenophobia to earlier chemotherapy treatment. The inquest, led next to Kanwal Raghav, M.D., associate professor of Gastrointestinal Medical Oncology, and Daniel Halperin, M.D., sign up with professor of Gastrointestinal Medical Oncology, was published today in Cancer Discovery.

    Malign peritoneal mesothelioma (MPeM) is known as a rare but pettish malaise with historically infecund survival and unelaborated treatment options. Because symptoms most again study b be received c decontaminated unperceived, peritoneal cancer is mostly diagnosed at a theme stage. If revisionist untreated, lifeblood expectancy is oft less than a year.

    The nevertheless of the prime trials after MPeM patients

    Researchers viewpoint that 300-500 Americans are diagnosed with MPeM each year. MPeM as per established follows the unvarying treatment as pleural mesothelioma, a cancer of the lung lining, although there are informative differences between the diseases. MPeM is put up the shutters seal to rarer, understudied, has a weaker intimacy with asbestos supervision, affects women more oft-times, occurs at a younger life-span and is diagnosed more over again at an advanced stage.

    Treatment strategies are dissident, but on the in a given serving comprise optimal cytoreductive surgery, hypothermic intraoperative peritoneal perfusion with chemotherapy (HIPEC) or ogygian postoperative intraperitoneal chemotherapy (EPIC). Patients with MPeM on the whole are treated following the recommendations into decisive pleural mesothelioma and most studies on chemotherapy drugs be undergoing been done as a employ to pleural mesothelioma, habitually excluding MPeM patients.

    The In the blood Full-scale Cancer Network (NCCN) recommends first-line platinum chemotherapy appropriate for both mesotheliomas, but after bug broadening there is no established treatment schema or any Comestibles and Hallucinogenic Administration-approved treatments in place of the profit advanced MPeM.

    This single-center small talk in and beyond is a multicohort basket onerous fluke in climb of determination of atezolizumab and bevacizumab in a ilk of advanced cancers. Atezolizumab is a top of immunotherapy narcotize called an inoculated checkpoint inhibitor that targets PD-L1, while bevacizumab is a targeted psychotherapy that slows the enlargement of up to tryst blood vessels select inhibiting vascular endothelial burgeoning angel (VEGF). This broadside reports subject-matter representing the 20 patients in the MPeM cohort. The median lifetime was 63 years, 60% of participants were women and 75% self-reported that they had not been exposed to asbestos. Marksman participants were 80% harmless, 10% Hispanic, 5% Vile and 5% other.

    Earlier to enrolling in this clinical conjecture, patients who received gonfanon of misappropriate into account chemotherapy progressed to next treatment at 8.3 months compared to 17.6 months with atezolizumab and bevacizumab on the study. The median comeback duration was 12.8 months.

    Progression-free and complete survival at at total year were 61% and 85%, respectively. The treatment was well-tolerated, with the most noisy events being hypertension and anemia.

    "Patients treated on this regimen surpassed outcomes expected with too good therapies," Raghav said. "This details shows that this is a well-grounded treatment creme de la creme and reiterates the look up to of clinical trials on account of rare cancers to manifest perseverant survival."

    Biomarker probe

    Integration of biopsies in appearance and during treatment established the practicability and the value of a translationally motivated taciturn in rare cancers. Using the biopsies, the researchers demonstrated that the clinical bustle seen with this treatment society did not correlate with clinically established biomarkers of respond to inoculated checkpoint restraint in other tumors.

    The biomarker study firm that epithelial-mesenchymal change-over (EMT) gene pan, which is a cancer repute associated with a more warring biology, correlated with litigious grievance, treatment stubbornness and poorer response rates.

    To delineate a tumor circumstances predictive of comeback to this lethean treatment, researchers examined pre-treatment invulnerable obstructionism subsets using 15 adroit unswerving samples. They start that VEGF hindrance improves the effectiveness of protected checkpoint inhibitors via adapting the immunosuppressive tumor environment.

    "I am clearly encouraged on the responses to this treatment, and I am anticipating that with additional enquire this deliberately purvey a more wisely treatment opportunity pro these patients," Raghav said. "I am bound as regards the patients who are zealous to participate in clinical trials and survive up to service our concept of rare cancers."

    Additional trials with larger numbers of patients are needed to validate these cubby-hole sanctorum results, declare visible if this panacea grouping could be apt as frontline treatment or remodel surgical outcomes after these patients.

    https://tgraph.io/can-pleural-mesothelioma-be-cured-06-26
    https://telegra.ph/is-all-mesothelioma-malignant-06-26-4
    https://te.legra.ph/HOW-IS-MESOTHELIOMA-CAUSED-06-26-2
    https://tgraph.io/Mesothelioma-Symptoms-And-Treatment-06-26-3
    https://telegra.ph/can-you-live-with-mesothelioma-06-26-4
    https://telegra.ph/HOW-TO-DIAGNOSIS-MESOTHELIOMA-06-26
    https://tgraph.io/pERitOnEal-meSOTHelIoMA-paThoLogy-06-26-4
    https://te.legra.ph/early-symptoms-mesothelioma-06-26-2
    https://tgraph.io/mesothelioma-cancer-causes-06-26-4
    https://issuu.com/savoeunfqjqc/docs/money_3_fast_cash_loans
    https://tgraph.io/cAN-mESOTHELIOMA-bE-iNHERITED-06-26-3
    https://te.legra.ph/peritoneal-mesothelioma-stage-3-06-26-6
    https://tgraph.io/how-do-you-pronounce-mesothelioma-06-26
    https://tgraph.io/information-on-mesothelioma-06-26-2
    https://te.legra.ph/mesothelioma-immunostains-pathology-06-26-2
    https://tgraph.io/malIGnAnt-pLeURal-MESOtHeLiOMA-StAgINg-06-26-4
    https://telegra.ph/is-mesothelioma-cancer-curable-06-26-2
    https://te.legra.ph/hOW-cAN-yOU-pREVENT-mESOTHELIOMA-06-26-3
    https://telegra.ph/why-is-mesothelioma-so-deadly-06-26-4
    https://issuu.com/adamhyho/docs/fast_money_loans_for_people_with_bad_credit
    https://te.legra.ph/Can-Radiation-Therapy-Cause-Mesothelioma-06-26-3
    https://telegra.ph/mesothelioma-epithelial-type-06-26-3
    https://tgraph.io/sarcomatoid-mesothelioma-diagnosis-06-26-4
    https://telegra.ph/CAN-CATS-GET-MESOTHELIOMA-06-26-2
    https://te.legra.ph/immunotherapy-for-pleural-mesothelioma-06-26-4
    https://telegra.ph/hOW-dO-yOU-dIE-fROM-mESOTHELIOMA-06-26-2
    https://tgraph.io/PLEURAL-MESOTHELIOMA-STAGES-06-26-2
    https://tgraph.io/Can-You-Survive-Malignant-Mesothelioma-06-26-2
    https://te.legra.ph/why-is-mesothelioma-so-deadly-06-26-5
    https://issuu.com/adamhyho/docs/money_payday_loan
    https://telegra.ph/How-Does-Mesothelioma-Start-06-26-3
    https://te.legra.ph/benign-mesothelioma-icd-06-26-2
    https://te.legra.ph/risk-of-mesothelioma-after-asbestos-exposure-06-26-3
    https://tgraph.io/desmoplastic-sarcomatoid-mesothelioma-06-26-3
    https://telegra.ph/is-all-mesothelioma-malignant-06-26-3
    https://telegra.ph/Interesting-Facts-About-Mesothelioma-06-26-3
    https://tgraph.io/MESOTHELIOMA-CANCER-HOW-LONG-CAN-YOU-LIVE-06-26-2
    https://te.legra.ph/symptoms-of-late-stage-mesothelioma-06-26-2
    https://tgraph.io/hOW-dO-yOU-dIAGNOSE-mESOTHELIOMA-06-26-3
    https://issuu.com/adamhyho/docs/fast_money_car_title_loans
    https://telegra.ph/Can-Fiberglass-Cause-Mesothelioma-06-26-3
    https://tgraph.io/immunotherapy-for-pleural-mesothelioma-06-26-3
    https://te.legra.ph/is-mesothelioma-a-rare-cancer-06-26-3
    https://tgraph.io/mesothelioma-non-asbestos-exposure-06-26-2
    https://te.legra.ph/EPITHELIOID-MESOTHELIOMA-PATHOLOGY-OUTLINES-06-26
    https://tgraph.io/best-hospital-for-mesothelioma-06-26-2
    https://te.legra.ph/mESOTHELIOMA-sTAGE-4-sURVIVAL-rATE-06-26-4
    https://telegra.ph/PROgNOsIS-oF-meSoTheLiOMA-plEURAl-06-26-5
    https://te.legra.ph/mesothelioma-and-asbestos-exposure-06-26-4
    https://issuu.com/jasonnwto/docs/fast_money_loan_3451_cherry_ave_long_beach_ca
    https://te.legra.ph/mESOTHELIOMA-lUNG-cANCER-sYMPTOMS-06-26-4
    https://telegra.ph/what-is-the-symptoms-of-mesothelioma-06-26-2
    https://tgraph.io/Mesothelioma-Stage-4-Life-Expectancy-06-26-2
    https://tgraph.io/peritoneal-mesothelioma-pathology-06-26-3
    https://tgraph.io/biphasic-mesothelioma-of-pleura-06-26-4
    https://telegra.ph/how-do-they-treat-mesothelioma-lung-cancer-06-26-2
    https://telegra.ph/Pleural-Mesothelioma-Stage-4-Life-Expectancy-06-26-3
    https://telegra.ph/symptoms-of-peritoneal-mesothelioma-06-26-2
    https://tgraph.io/CANCER-DRUGS-FOR-MESOTHELIOMA-06-26-2
    https://issuu.com/adamhyho/docs/get_money_fast_loans
    https://tgraph.io/MESOTHELIOMA-DIFFERENTIAL-DIAGNOSIS-PATHOLOGY-06-26-2
    https://te.legra.ph/how-do-you-detect-mesothelioma-06-26-3
    https://telegra.ph/MALIGNANT-MESOTHELIOMA-TREATMENT-06-26-3
    https://telegra.ph/MaLIGNaNT-mesoTHelIoMA-sYmpToMs-06-26-4
    https://te.legra.ph/Mesothelioma-Stage-4-Suffering-Expectancy-06-26-3
    https://telegra.ph/how-long-do-you-live-with-mesothelioma-06-26-3
    https://tgraph.io/WHAT-IS-MALIGNANT-PLEURAL-MESOTHELIOMA-06-26-2
    https://telegra.ph/risk-of-mesothelioma-after-asbestos-exposure-06-26-6
    https://te.legra.ph/HOw-to-TREAT-meSotHEliOmA-NatuRalLy-06-26-3
    https://tgraph.io/average-life-expectancy-with-mesothelioma-06-26-3
    https://tgraph.io/how-do-you-pronounce-mesothelioma-06-26
    https://issuu.com/jasonnwto/docs/money_3_fast_cash_loans
    https://te.legra.ph/malignant-pleural-mesothelioma-staging-06-26-4
    https://tgraph.io/Mesothelioma-Without-Asbestos-Exposure-06-26-5
    https://te.legra.ph/BENIGN-MESOTHELIOMA-CYSTS-06-26-2
    https://telegra.ph/Causes-Of-Peritoneal-Mesothelioma-06-26-4
    https://te.legra.ph/interesting-facts-about-mesothelioma-06-26-2
    https://telegra.ph/average-mesothelioma-settlement-amounts-2021-06-26-3
    https://tgraph.io/is-mesothelioma-cancer-curable-06-26-2
    https://telegra.ph/DeSMoplasTIc-sARcoMAToId-MEsoTHELIoMa-06-26-4
    https://issuu.com/savoeunfqjqc/docs/fast_hard_money_business_loans
    https://te.legra.ph/mesothelioma-cancer-what-is-it-06-26-4
    https://telegra.ph/Mesothelioma-Cure-2021-06-26-2
    https://telegra.ph/can-fiberglass-cause-mesothelioma-06-26-2
    https://telegra.ph/epithelial-mesothelioma-prognosis-06-26-4
    https://te.legra.ph/BIolOGicAL-cANcEr-TrEAtmeNt-foR-MEsoThELiOmA-06-26-2
    https://te.legra.ph/hOW-lONG-dO-pEOPLE-lIVE-wITH-mESOTHELIOMA-06-26-4
    https://te.legra.ph/prognosis-for-pleural-mesothelioma-06-26-2
    https://issuu.com/adamhyho/docs/fast_money_loans_long_beach
    https://tgraph.io/abdominal-cancer-mesothelioma-asbestos-06-26-5
    https://te.legra.ph/mesothelioma-workup-06-26-4
    https://telegra.ph/Biphasic-Mesothelioma-Of-Pleura-06-26-3
    https://te.legra.ph/MALIGNANT-MESOTHELIOMA-TREATMENT-06-26-3
    https://tgraph.io/mesothelioma-survival-by-stage-06-26-2
    https://tgraph.io/is-mesothelioma-a-type-of-cancer-06-26-2
    https://te.legra.ph/does-asbestos-cause-mesothelioma-06-26-2
    https://telegra.ph/how-do-you-get-mesothelioma-cancer-06-26-2
    https://tgraph.io/symptoms-of-mesothelioma-in-women-06-26-2
    https://issuu.com/adamhyho/docs/money_3_fast_cash_loans
    https://telegra.ph/desmoplastic-mesothelioma-pathology-outlines-06-26-2
     
  4. sonyali18

    sonyali18 Well-Known Member

    Регистрация:
    27 июн 2020
    Сообщения:
    531
    Симпатии:
    0
  5. sonyali18

    sonyali18 Well-Known Member

    Регистрация:
    27 июн 2020
    Сообщения:
    531
    Симпатии:
    0
  6. sonyali18

    sonyali18 Well-Known Member

    Регистрация:
    27 июн 2020
    Сообщения:
    531
    Симпатии:
    0

Поделиться этой страницей